Skip to content

Author

Ana López

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world treatment pathways and outcomes in metastatic NSCLC across Spanish hospitals: Insights from the ECO-ARWEN study.

716 Background: Real-world evidence can help evaluate whether advances in oncology care are being consistently translated into routine clinical practice. The rapid evolution of immunotherapy and targeted therapies has reshaped the management of metastatic non-small cell lung cancer (mNSCLC). However, the extent...

Á. Rogado, Rocio Casado, C. Camps et al. · 0 citations
Open access Sep 2026

Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer

Abstract Background Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment. Understanding the tumor-immune interactions that dictate sensitivity to PD-1 blockade is essential for improving outcomes and optimizing immunotherapy personalization. Methods We performed compartment-specifi...

C. Fernández-Luna, J. Baena, A. Calles et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.